Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2002 Apr;3(4):349-54.
doi: 10.1093/embo-reports/kvf070. Epub 2002 Mar 15.

An episomally replicating vector binds to the nuclear matrix protein SAF-A in vivo

Affiliations

An episomally replicating vector binds to the nuclear matrix protein SAF-A in vivo

Bok Hee C Jenke et al. EMBO Rep. 2002 Apr.

Abstract

pEPI-1, a vector in which a chromosomal scaffold/matrix-attached region (S/MAR) is linked to the simian virus 40 origin of replication, is propagated episomally in CHO cells in the absence of the virally encoded large T-antigen and is stably maintained in the absence of selection pressure. It has been suggested that mitotic stability is provided by a specific interaction of this vector with components of the nuclear matrix. We studied the interactions of pEPI-1 by crosslinking with cis-diamminedichloroplatinum II, after which it is found to copurify with the nuclear matrix. In a south-western analysis, the vector shows exclusive binding to hnRNP-U/SAF-A, a multifunctional scaffold/matrix specific factor. Immunoprecipitation of the crosslinked DNA-protein complex demonstrates that pEPI-1 is bound to this protein in vivo. These data provide the first experimental evidence for the binding of an artificial episome to a nuclear matrix protein in vivo and the basis for understanding the mitotic stability of this novel vector class.

PubMed Disclaimer

Figures

None
Fig. 1. (A) Restriction maps of pEPI-1 and pGFP-C1. Arrows indicate the positions of primers used for PCR analysis. (B) South-western analysis after nuclear fractionation using either pEPI-1 or pGFP-C1 as a probe. Only binding to fractions 2 (soluble nuclear proteins) and 5 (nuclear matrix) is shown. Lanes 1 and 2, binding of pEPI-1 to fractions 2 and 5, respectively; lanes 3 and 4, binding of pGFP-C1 to fractions 2 and 5, respectively.
None
Fig. 2. PCR analysis from DNA bound to HAP or the supernatant after crosslinking of CHO cells transfected with either pEPI-1 or pGFP-C1. (A) PCR analysis of HAP-bound DNA. Lane 1, molecular weight marker; lane 2, control PCR using 1 ng of pEPI-1 vector DNA as a template; lane 3, PCR analysis from pEPI-1 transfected cells using 10 ng of DNA as a template; lane 4, PCR analysis from pGFP-C1 transfected cells using 10 ng of DNA as a template; lane 5, as lane 4 but using 100 ng of DNA as a template. (B) PCR analysis of the supernatant from pEPI-1 transfected cells using 10 ng of DNA as a template. Designations are as in (A).
None
Fig. 3. South-western analysis of HAP-bound proteins and proteins of the supernatant after crosslinking with cis-DDP using either pEPI-1 or pGFP-C1 as a probe. Lane 1, pEPI-1 bound to supernatant proteins; lane 2, pEPI-1 bound to HAP-bound proteins; lane 3, pGFP-C1 bound to supernatant proteins; lane 4, pGFP-C1 bound to HAP-bound proteins. Lanes 1–4, binding was performed in the presence of a 10-fold excess of competitor DNA. Lane 5, as lane 2; lane 6, as lane 4. Lanes 5 and 6, binding was performed in the presence of a 100-fold excess of competitor DNA. Lane 7, western analysis of HAP-bound proteins using an anti-SAF-A antibody. Conditions for western and south-western analyses are described in the Methods.
None
Fig. 4. (A) Western analysis using an anti-SAF-A antibody from proteins isolated from immunoprecipitates with an anti-SAF-A antibody of HAP-bound DNA–protein complexes after cis-DDP crosslinking of cells transfected with either pEPI-1 or pGFP-C1. Lane 1, total nuclear proteins from untransfected CHO cells; lane 2, proteins isolated from pEPI-1 transfected cells; lane 3, proteins isolated from pGFP-C1 transfected cells. (B) PCR analysis after immunoprecipitation with an anti-SAF-A antibody of HAP-bound DNA–protein complexes after cis-DDP crosslinking of cells transfected with either pEPI-1 or pGFP-C1. Lane 1, molecular weight marker; lane 2, control PCR using 1 ng of pEPI-1 vector DNA as template; lane 3, PCR analysis of immunoprecipitate from 5 × 107 pEPI-1 transfected cells; lane 4, PCR analysis of immunoprecipitate from 5 × 107 pGFP-C1 transfected cells. (C) Western analysis with an anti-SAF-A antibody of proteins after immunoprecipitation with non-specific antibodies (anti-Oxytricha βTP). Lane 1, proteins from the supernatant after immunoprecipitation; lane 2, proteins from immunoprecipitate. A similar result was obtained when immunoprecipitation was performed with an anti-rabbit IgG.

Similar articles

Cited by

References

    1. Adachi Y., Kas, E. and Laemmli, U.K. (1989) Preferential, cooperative binding of DNA topoisomerase II to scaffold-associated regions. EMBO J., 8, 3997–4006. - PMC - PubMed
    1. Baiker A., Maercker, C., Piechaczek, C., Schmidt, S.B., Bode, J., Benham, C. and Lipps, H.J. (2000) Mitotic stability of an episomal vector containing a human scaffold/matrix-attached region is provided by association with nuclear matrix. Nature Cell Biol., 2, 182–184. - PubMed
    1. Bode J., Benham, C., Knopp, A. and Mielke, C. (2000) Transcriptional augmentation: modulation of gene expression by scaffold/matrix-attached regions (S/MAR elements). Crit. Rev. Eukaryot. Gene Expr., 10, 73–90. - PubMed
    1. Bode J., Fetzer, C.P., Nehlsen, K., Scinteie, M., Hinrichsen, B.H., Baiker, A., Piechazcek, C., Benham, C. and Lipps, H.J. (2001) The Hitchhiking Principle: optimizing episomal vectors for use in gene therapy and biotechnology. Int. J. Gene Ther. Mol. Biol., 6, 33–46.
    1. Bubley G.J., Xu, J., Kupiec, N., Sanders, D., Foss, F., O’Brien, M., Emi, Y., Teicher, B.A. and Patiemo, S.R. (1996) Effect of DNA conformation on cisplatin adduct formation. Biochem. Pharmocol., 51, 717–721. - PubMed

Publication types

Substances